- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
AMA Will Issue New CPT Code for AI Prostate Cancer Mapping Tool
The Current Procedural Terminology (CPT) Category III code for the Unfold AI prostate cancer mapping platform can be utilized by radiologists starting in July 2024.
The 2024 Current Procedural Terminology (CPT) codes from the American Medical Association (AMA) will include a new category III CPT code for the use of Unfold AI, an artificial intelligence (AI)-enabled mapping platform for prostate cancer imaging.
Unfold AI is reportedly the first AI-powered prostate cancer modality to receive a category III CPT code, according to Avenda Health, the manufacturer of Unfold AI.1
Avenda Health said the X237T CPT code, which goes into effect in July 2024, can be utilized for “Non-invasive prostate cancer estimation map, derived from augmentative analysis of image-guided fusion biopsy and pathology, including visualization of margin volume and location, with margin determination and physician interpretation and report.”
"The new CPT code solidifies our position as a frontrunner in revolutionizing cancer care and our commitment to making our technology accessible to all patients,” noted Brittany Berry-Pusey, Ph.D., the COO and co-founder of Avenda Health.
In a retrospective study published earlier this year, researchers found that AI model margins with Unfold AI demonstrated a 96.9 percent sensitivity for diagnosing clinically significant prostate cancer (csPCa) in comparison to 37.4 percent for regions of interest (ROI) on conventional magnetic resonance imaging (MRI).2
References
1. Avenda Health. Avenda Health’s revolutionary AI mapping tool for prostate cancer achieves landmark category III CPT code designation. Cision PR Newswire. Available at: https://www.prnewswire.com/news-releases/avenda-healths-revolutionary-ai-mapping-tool-for-prostate-cancer-achieves-landmark-category-iii-cpt-code-designation-301973699.html . Published November 1, 2023. Accessed November 1, 2023.
2. Hall J. Study says AI mapping more effective than MRI for assessing extent of prostate cancer. Diagnostic Imaging. Available at: https://www.diagnosticimaging.com/view/study-says-ai-mapping-more-effective-than-mri-for-assessing-extent-of-prostate-cancer . Published June 15, 2023. Accessed November 1, 2023.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Study Emphasizes PSMA PET Staging of High-Risk, Hormone Sensitive Prostate Cancer
January 4th 2025In patients with high-risk, hormone sensitive prostate cancer who had no evidence of metastasis on conventional imaging, PSMA PET revealed polymetastatic disease in 24 percent of patients and M1 disease staging in 46 percent of patients.
Can MRI and Micro-Ultrasound Guidance Bolster Focal Laser Ablation Outcomes for Prostate Cancer?
January 3rd 2025For patients with localized prostate cancer and PI-RADS 3 or higher lesions, MRI-guided micro-ultrasound multifiber focal laser ablation had an 18 percent recurrence rate at one year, according to newly published research.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.
